News
Videos
Conferences
Events
Resources
Subscribe

|Videos|December 29, 2022

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s)Ruben Mesa, M.D., Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Episodes in this series

Experts on MPNs

EP. 1 A Background on Myeloproliferative Neoplasms

Expert on MPNs

EP. 2 How Are Myeloproliferative Neoplasms Diagnosed?

Expert on MPNs

EP. 3 Overview on the Management of Essential Thrombocythemia and Polycythemia Vera

Experts on MPN

EP. 4 Overview of Treatment Options for Myelofibrosis

Expert on MPNs

EP. 5 Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

Expert on MPNs

EP. 6 Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Experts on MPNs

EP. 7 Novel Treatment Strategies in Essential Thrombocythemia and Polycythemia Vera

Expert on MPNs

EP. 8 Myelofibrosis: Novel Treatment Strategies and Combination Therapies

Expert on MPNs

EP. 9 MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia: © stock.adobe.com.

Besremi Recognized by Updated Guidelines for Essential Thrombocythemia

January 28th 2026

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Helping You Understand Stage 2 Essential Thrombocythemia

January 25th 2026

The FDA has granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer: © stock.adobe.com.

FDA Orphan Drug Designation Granted to Zavabresib for Myelofibrosis

January 22nd 2026

Image of "FDA"

FDA Accepts Besremi Application for Essential Thrombocythemia

BySpencer Feldman

January 13th 2026

Mayra Andujar-Delgado shares her 10-year myelofibrosis journey and how 2025 Blood Cancer Hero Dr. Faseeh Khaja empowered her and her husband.

A Decade of Patient Proactivity and Physician Partnership

ByMayra Andujar-Delgado

January 11th 2026

Trending on CURE

FDA Updates Safety Warnings for Common Chemotherapy Drugs

FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma

Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us

Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma

KTX-1001 Elicits Responses in Some With Multiple Myeloma